News|Videos|June 28, 2022

AUPN Leadership Minute Episode 23: Time Savers for Chairs

Author(s)Donald S. Higgins, Jr., MD, Jun Li, MD, PhD

Episode 23 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA and Albany Medical College; and Jun Li, MD, PhD, of Houston Methodist Hospital. [WATCH TIME: 3 minutes]

WATCH TIME: 3 minutes

AUPN's Leadership Minute is a brief, highly focused summary of practical advice for Chairs, Program Directors and other leaders in academic neurology, available as both mini-podcasts and in short form videos.

The goal of this program is to provide relevant and useful information in a modicum of time, designed to fit seamlessly into our very busy schedules.

This podcast reviews how to equip chairs with skills for success, ways to use delegation to improve your efficiency as a chair and be a more effective leader and discusses strategies to improve your administrative team.

Click here to access the full PowerPoint presentation for the episode.

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related to this article

November 4th, 2026

Distinguishing Lambert-Eaton Myasthenic Syndrome From Ocular Myasthenia Gravis in the Eye Clinic

Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.

October 29th, 2026

World Stroke Day: Preventing Perioperative Stroke With Predictive Tools

Shadi Yaghi, MD, FAHA, Chair of Neurology at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center, discusses a new calculator that predicts stroke risk within 30 days of a procedure.

October 29th, 2026

Incorporating the Updated AAN/AHS Migraine Prevention Guideline Into Practice

The clinical professor of neurology and pediatrics at The Ohio State University Wexner Medical Center discussed payer step therapy, earlier preventive treatment, and questions the updated guideline leaves open.

October 29th, 2026

World Stroke Day 2026: Closing the Gap Between Stroke Onset and the Emergency Call Number

Brian Snelling, MD, director of the stroke program at Marcus Neuroscience Institute discussed delays in calling 911 after stroke onset, gaps in awareness of atypical symptoms, and how to reach underserved populations.

October 28th, 2026

NeuroVoices: Bruce Ovbiagele, MD, MSc, MAS, MBA, on the Future of Stroke Publishing

The Editor-in-Chief of the Journal of the American Heart Association discussed what journal editors look for in stroke research submissions, how AI and open access are reshaping publishing, and the equity gaps that still exist for researchers in lower-income countries.

October 27th, 2026

Collective Advocacy, Shared Priorities, and What’s Ahead at MDA 2027

Paul Melmeyer, MPP, Executive Vice President of Public Policy and Advocacy at the Muscular Dystrophy Association, discusses the Neuromuscular Advocacy Collaborative, its growing year-round presence, and what the group hopes to accomplish heading into the 2027 MDA Clinical and Scientific Conference.

November 4th, 2026

IJMSC Webinar Series Guides MS Clinicians From Idea to Publication

IJMSC editor-in-chief, François Bethoux, MD, and colleagues cover idea generation, poster conversion, literature reviews, and peer review in a 4-part webinar series for MS clinicians.

November 4th, 2026

Final Results Reported for EPISOD1 Trial of SOD1-ALS Gene Therapy AMT-162

uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.

AUPN Leadership Minute Episode 23: Time Savers for Chairs

Related to this article

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study

AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS

FDA Grants Priority Review to Huntington Disease Gene Therapy BLA

Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development

NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease